METHODS FOR PREDICTING RELATIVE BENEFIT OF THERAPY OPTIONS AND DEVICES THEREOF

METHODS FOR PREDICTING RELATIVE BENEFIT OF THERAPY OPTIONS AND DEVICES THEREOF

Methods, non-transitory computer-readable media, and devices are disclosed that identify and validate a signature for predicting relative benefit of two therapies for frontline and therapy sequencing for patients. Described and illustrated by way of the example herein are machine learning approaches...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BLAIS, Edik Matthew, NGUYEN, Hieu Trung, PETRICOIN III, Emanuel Frank
Format: Patent
Sprache:eng
Schlagworte:
HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATIONTECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING ORPROCESSING OF MEDICAL OR HEALTHCARE DATA
INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS
PHYSICS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Methods, non-transitory computer-readable media, and devices are disclosed that identify and validate a signature for predicting relative benefit of two therapies for frontline and therapy sequencing for patients. Described and illustrated by way of the example herein are machine learning approaches for gaining data-driven insights from the mutational landscape in metastatic pancreatic adenocarcinoma (mPDAC) and validating the signature in predicting relative benefit from FOLFIRINOX (FFX) and Gemcitabine/nab-Paclitaxel (GA) therapies. This technology inputs a patient's genomics findings and clinical data and generates predictions of relative effectiveness for the two distinct FFA and GA chemotherapy options. The predictions for an individual patient provide personalized guidance on treatment sequencing to improve patient health outcomes.